Skip to content
You are now leaving to visit

Ionis’ License Agreement for Huntington’s Disease Drug, IONIS-HTT Rx, Receives HSR Clearance

Ionis Earns $45 Million License Fee CARLSBAD, Calif. , Dec. 18, 2017 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that its license agreement with Roche to develop and commercialize IONIS-HTT Rx for the treatment of people with Huntington’s disease (HD) has received